The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema ... that treats eye diseases, so patients don’t need frequent injections.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment ... the ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections ... hemorrhage. Susvimo is also indicated for the treatment of neovascular (wet) age-related macular ...

4-6 Susvimo is now available to US retina specialists and their patients with DME. “Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...